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patients were initiated on 25mg of RLAI. At 12-months 63% 
of patients were still on RLAI. The reasons for discontinuation
were lack of response (14%); loss-to-follow-up (10.5%); other
(7.5%); patient or family choice (6%); adverse events (6%); tol-
erability (2%); and adherence (1.5%). Young age at schizophre-
nia onset and suicidal behavior at baseline were signiﬁcant risk
factors for time to discontinuation (p < 0.04). CONCLUSIONS:
The treatment continuation rate with RLAI at 12-months is con-
sistent with the results of Fleischhacker et al (2003), but supe-
rior to oral typical and atypical agents (Lieberman et al, 2005).
Fleischhacker et al (2003); J Clin Psychiatry 64(10):1250–1257.
Lieberman et al (2005); NEJM 353:1209–23.
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OBJECTIVE: To summarize rates of clinical remission and
dropouts/withdrawal due to adverse drug reactions (ADRs) or
lack of efﬁcacy/effectiveness (LoE) of serotonin-norepinephrine
reuptake inhibitors (SNRIs), selective serotonin reuptake inhibi-
tors (SSRIs) and tricyclic antidepressants (TCAs). METHODS:
We searched Medline, Embase, International Pharmaceutical
Abstracts, and The Cochrane International Library from 1980
to 2005 for clinical trials using MeSH terms “serotonin norepi-
nephrine reuptake inhibitors”, “selective serotonin reuptake
inhibitors”, “tricyclic antidepressants”, “major depression”, and
“clinical remission”. Accepted languages were English, French,
German, Portuguese, and Spanish. A meta-analytic approach
was used to synthesize outcome rates from published head-to-
head clinical trials comparing two or more drugs (in therapeutic
doses) from SNRIs, and/or SSRIs, and/or TCAs from 6 to 12
weeks of treatment. Remission was deﬁned as a ﬁnal score = <7
on the Hamilton Depression Rating Scale or = <12 in the 
Montgomery-Asberg Depression Rating Scale. Data were 
combined across arms of individual studies using a random
effects model, producing point estimates with 95% conﬁdence
intervals. RESULTS: Data were gathered from 30 arms of 15
head-to-head trials of 2524 patients. TCAs had the highest
overall remission rate (45.7%), followed by SNRIs (45.0%), and
SSRIs (38.8%) (p > 0.05 for TCAs versus SNRIs; p < 0.001 for
TCAs versus SSRIs; and p < 0.001 for SNRIs versus SSRIs).
When patients were categorized as inpatients (n = 582) and out-
patients (n = 1613), SNRIs had the highest remission rate (52.0%
for 144 inpatients and 49.3% for 559 outpatients). SNRIs had
the lowest overall discontinuation rates (24.3%), followed by
SSRIs (27.1%), and TCAs (34.9%). Rates of discontinuation due
to ADRs and LoE were 9.8% and 5.2% for SNRIs, 7.3% and
7.0% for SSRIs, and 18.9% and 9.1% for TCAs, respectively. 
CONCLUSIONS: SNRIs have the highest efﬁcacy/effectiveness
remission rates (statistically signiﬁcant for inpatients and 
outpatients), and the lowest overall dropout/withdrawal rates 
suggesting clinical superiority for this class in treating major
depressive disorders.
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OBJECTIVE: While SGA therapy has been associated with new-
onset diabetes, the relative risk of the agents and the impact of
possible confounding variables have been questioned. This study
evaluated the impact of dose and treatment indication on the 
relative risk of new-onset diabetes associated with SGA therapy
while controlling for demographic, clinical and medication vari-
ables. METHODS: A retrospective database analysis capturing
electronic medical records for adult Texas Medicaid enrollees
taking antipsychotic monotherapy from January 1997 to 
December 2001, with a maximum follow-up of 12 months was
used. Patients were stratiﬁed according to treatment dose (low,
medium, high) and a hierarchy of mutually exclusive diagnostic
categories: schizophrenia, bipolar disorder, dementia, psychotic
disorder, non-psychotic disorder and no mental health indica-
tion. The incidence of diabetes was examined using multivariate
logistic regression analysis. RESULTS: Data were available for
13,731 patients. At treatment-onset, the prevalence of diabetes
was 16.9%. The mean (SD) dose by indication for the most
prevalent conditions (schizophrenia, bipolar disorder and
dementia, respectively) were as follows: olanzapine (12.04mg
(6.73); 8.91mg (5.78); 4.87mg (3.00)); quetiapine (273.16mg
(203.86); 146.33mg (142.29); 79.59 (82.57)); and risperidone
(3.55mg (2.37); 2.05 (1.76); 1.12 (0.85)). The overall incidence
of diabetes was 2.6%. Multivariate logistic regression analysis
showed no difference in the incidence of diabetes according to
the agent used (p = 0.281). Compared to risperidone, the odds
of new-onset diabetes were 0.879 (95% CI: 0.653 to 1.184) and
0.683 (95% CI: 0.414 to 1.126) for olanzapine and quetiapine,
respectively. Neither treatment indication (p = 0.876) nor
antipsychotic dose (p = 0.274) were associated with the devel-
opment of diabetes. CONCLUSIONS: Results indicate that the
risk of new-onset diabetes does not differ among SGA agents
(i.e., olanzapine, quetiapine and risperidone). While the dose of
antipsychotic prescribed varied signiﬁcantly according to treat-
ment indication and patient age, neither dose nor indication were
associated with the development of diabetes.
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OBJECTIVES: Atypical antipsychotic-induced diabetes has
raised concerns recently, while the extent of atypical 
antipsychotic-induced diabetes mellitus among Asians with
schizophrenia is not well known. This study aims to compare the
association of atypical antipsychotic treatments and diabetes
mellitus with that of haloperidol treatment and diabetes mellitus
among schizophrenic patients in Taiwan. METHODS: Data used
in this study came from Taiwan’s National Health Insurance
claims database for the period 2000–2004. This study identiﬁed
antipsychotic treatment episodes of clozapine, olanzapine,
risperidone, quetiapine, amisulpride, ziprasidone, and haloperi-
